[{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Samuraciclib","moa":"||CDK7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Carrick Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Carrick Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Samuraciclib","moa":"||CDK7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Carrick Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Carrick Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cavrotolimod","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Exicure \/ Inapplicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Cavrotolimod","moa":"||Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exicure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Exicure \/ Inapplicable"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CT7439","moa":"CDK12\/13","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carrick Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Carrick Therapeutics \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : CT7439 is a best-in-class novel cyclin-dependent kinase 12/13 inhibitor, which is being evaluated for the treatment of multiple neoplasms.

                          Product Name : CT7439

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 23, 2024

                          Lead Product(s) : CT7439

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : CT7001 (samuraciclib) is a first-in-class oral CDK7 inhibitor evaluated with ARV-471 (vepdegestrant) for ER+, HER2- metastatic breast cancer treatment.

                          Product Name : CT7001

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 14, 2024

                          Lead Product(s) : Samuraciclib,Vepdegestrant

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : CT7001 (samuraciclib) is an oral and first-in-class inhibitor of CDK7, and the Menarini Group's (Menarini) oral selective estrogen receptor degrader (SERD), elacestrant, in patients with CDK4/6i resistant HR+, HER2- metastatic breast cancer.

                          Product Name : CT7001

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 18, 2023

                          Lead Product(s) : Samuraciclib,Elacestrant DiHCl

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : The Company intends to use the proceeds to fund ongoing and planned CT7001 (samuraciclib) clinical trials, ongoing development of its CDK12/13 inhibitor / Cyclin-K glue-degrader, and for working capital and general corporate purposes.

                          Product Name : CT7001

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 12, 2022

                          Lead Product(s) : Samuraciclib,Fulvestrant

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Arch Ventures

                          Deal Size : $25.0 million

                          Deal Type : Series C Financing

                          blank

                          05

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : CT7001 (samuraciclib), an oral CDK7 inhibitor, is a promising therapeutic strategy in cancer, as CDK7 regulates transcription of cancer-causing genes and promotes uncontrolled cell cycle progression and resistance to anti-hormone therapy.

                          Product Name : CT7001

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 12, 2022

                          Lead Product(s) : Samuraciclib,Fulvestrant

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Pfizer Inc

                          Deal Size : $35.0 million

                          Deal Type : Financing

                          blank

                          06

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : Under the terms of the agreement, Pfizer will provide global development capabilities and expertise to support Carrick’s Phase 2 study of CT-7001 (samuraciclib) in combination with fulvestrant for CDK4/6i-resistant HR+, HER2- advanced breast cancer.

                          Product Name : CT7001

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 12, 2022

                          Lead Product(s) : Samuraciclib,Fulvestrant

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Pfizer Inc

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          07

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : Samuraciclib inhibiting CDK7 is a promising therapeutic strategy in cancer as CDK7 regulates the transcription of cancer-causing genes, promotes uncontrolled cell cycle progression and resistance to anti-hormone therapy.

                          Product Name : CT7001

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 22, 2021

                          Lead Product(s) : Samuraciclib,Fulvestrant

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : The fast track designations for cavrotolimod has been granted for two development programs: cavrotolimod in combination with anti-PD-1 therapy for metastatic Merkel cell carcinoma and cavrotolimod in combination with anti-PD-(L)1) therapy in cutaneous sq...

                          Product Name : AST-008

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          November 01, 2021

                          Lead Product(s) : Cavrotolimod,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : Clinical data on samuraciclib (CT7001), an oral and first-in-class inhibitor of CDK7, regulates the transcription of cancer-causing genes,support its continued development in breast cancer.

                          Product Name : CT7001

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 12, 2021

                          Lead Product(s) : Samuraciclib,Fulvestrant

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : Carrick Therapeutics is going to present two posters (i) Study of samuraciclib in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (ii) First in human, modular study of samuraciclib in advanced ...

                          Product Name : CT7001

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 17, 2021

                          Lead Product(s) : Samuraciclib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank